Lucid Diagnostics Inc. (LUCD)

Market Cap	137.23M
Revenue (ttm)	4.35M
Net Income (ttm)	-53.03M
Shares Out	86.86M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	689,613
Open	1.580
Previous Close	1.590
Day's Range	1.500 - 1.600
52-Week Range	0.630 - 1.633
Beta	1.34
Analysts	Strong Buy
Price Target	3.75 (+137.34%)
Earnings Date	Mar 24, 2025

About LUCD

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in a...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 14, 2021
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: LUCD
• Website: https://www.luciddx.com

Financial Performance

In 2024, Lucid Diagnostics's revenue was $4.35 million, an increase of 79.00% compared to the previous year's $2.43 million. Losses were -$53.03 million, 0.68% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for LUCD stock is "Strong Buy." The 12-month stock price forecast is $3.75, which is an increase of 137.34% from the latest price.

Price Target

$3.75

(137.34% upside)

Analyst Consensus: Strong Buy